Heart failure as first sign of development of cardiac metastases in a patient with diagnosis of papillary thyroid carcinoma on treatment with tyrosine-kinase inhibitors: differential diagnoses and clinical management.

Bruixola, Gema; Segura, Angel; Caballero, Javier; Andrés, Ana; Reche, Encarnación; Escoín, Corina; Díaz-Beveridge, Roberto

Bruixola, Gema; Segura, Angel; Caballero, Javier; Andrés, Ana; Reche, Encarnación; Escoín, Corina; Díaz-Beveridge, Roberto.

Afiliação

Bruixola G; Medical Oncology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.
Segura A; Medical Oncology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.
Caballero J; Medical Oncology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.
Andrés A; Cardiology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.
Reche E; Medical Oncology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.
Escoín C; Medical Oncology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.
Díaz-Beveridge R; Medical Oncology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.

Case Rep Oncol ; 7(2): 591-9, 2014 May.

Article em En | MEDLINE | ID: mdl-25298765

Palavras-chave

Cardiac magnetic resonance; Cardiac metastases; Sorafenib; Sunitinib; Thyroid cancer; Tyrosine-kinase inhibitors

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Case Rep Oncol Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Espanha País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google